Refine your search
Collections
Co-Authors
Journals
Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Kumar, Vinod
- Successful Application of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) after Intraoperative Occurrence of Malignant Hyperthermia in a Patient of Uterine Leiomyosarcoma for Cytoreduction Surgery
Abstract Views :239 |
PDF Views:64
Authors
Affiliations
1 Department of Onco-Anaesthesiology and Palliative Medicine, Dr BRAIRCH, All India Institute of Medical Sciences, New Delhi, IN
1 Department of Onco-Anaesthesiology and Palliative Medicine, Dr BRAIRCH, All India Institute of Medical Sciences, New Delhi, IN
Source
Central Journal of ISA, Vol 1, No 2 (2017), Pagination: 94-97Abstract
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is a technique used in combination with cytoreductive surgery to treat various cancers with local spread and not fully resectable. Anaesthetic complications are common during this procedure with disturbances in haemodynamics, coagulation, respiratory gas exchange and impact on various body systems. Sudden increase in temperature may be related to occurrence of Malignant Hyperthermia (MH) and remains a challenge requiring immediate recognition and aggressive management. We hereby report a case of hyperthermia in a patient posted for cytoreduction and HIPEC surgery emphasizing that a prompt identification; rational symptomatic and supportive therapy can be lifesaving.Keywords
Anaesthesia, Cytoreduction, Hyperthermia, Hyperthermic Intraperitoneal Chemotherapy.Full Text
References
- Rosenberg H, Davis M, James D, Pollock N, Stowell K. Malignant hyperthermia. Orphanet J Rare Dis. 2007; 2:21. https://doi.org/10.1186/1750-1172-2-21 PMid:17456235 PMCid:PMC1867813.
- Gillard EF, Otsu K, Fujii J, Khanna VK, de Leon S, Derdemezi J, et al. A substitution of cysteine for arginine 614 in the ryanodine receptor is potentially causative of human malignant hyperthermia. Genomics. 1991; 11:751–5. https://doi.org/10.1016/0888-7543(91)90084-R.
- Sugarbaker PH, van der Speeten K, Stuart OA. Pharmacologic rationale for treatments of peritoneal surface malignancy from colorectal cancer. World J Gastrointest Oncol. 2010; 2:19–30. https://doi.org/10.4251/ wjgo.v2.i1.19 PMid:21160813 PMCid:PMC2999152.
- Glahn KP, Ellis FR, Halsall PJ, Muller CR, Snoeck MM, Urwyler A, Wappler F. Recognizing and managing a malignant hyperthermia crisis: guidelines from the European Malignant Hyperthermia Group. Br J Anaesth. 2010; 105:417–20. https://doi.org/10.1093/bja/aeq243 PMid:20837722.
- Hopkins PM. Malignant hyperthermia: Pharmacology of triggering Br J Anaesth. 2011; 107:48–56. https://doi.org/10.1093/bja/aer132 PMid:21624965.
- Larach MG. North American Malignant Hyperthermia Group. Aclinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology. 1994; 80:771–9. https://doi.org/10.1097/00000542199404000-00008 PMid:8024130.
- Coccolini F, Corbella D, Finazzi P, Catena F, Germandi C, Melotti MR, Sonzogni V, Ansaloni L. Perioperative management of patients undergoing cytoreduction surgery and hyperthermic intraperitoneal chemotherapy. Canc Oncol Res. 2014; 2:29–34.
- Allen GC, Larach MG, Kunselman AR. The sensitivity and specificity of the caffeine-halothane contracture test: A report from the North American Malignant Hyperthermia Registry. The North American Malignant Hyperthermia Registry of MHAUS. Anesthesiology. 1998; 88:579–88. https://doi.org/10.1097/00000542-199803000-00006 PMid:9523799
- Issacs H, Badenhorst M. False-negative results with muscle caffeine halothane contracture testing for malignant hyperthermia. Anesthesiology. 993; 79:5–9. https://doi.org/10.1097/00000542-19930700000003.